Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Key Highlights
- ➤1-for-7 reverse stock split effective October 20, 2026
- ➤Revelation (REVB) targets Nasdaq minimum bid compliance
- ➤Post-split trading retains existing REVB symbol
- ➤Fractional shares rounded up to nearest whole share
Expert Statements
Chester Zygmont, III, Chief Financial Officer of Revelation Biosciences Inc.
“Chester Zygmont, III”
Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026
Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “REVB.” The CUSIP number for the common stock following the reverse stock split will be 76135L887.
Get started
Create a free account to read the full story.